ICH Q4B Annex 7(R2): Dissolution Test Guide
ICH Q4B Annex 7(R2) explains when the pharmacopoeial dissolution test chapters of the European Pharmacopoeia, Japanese Pharmacopoeia, and United States Pharmacopeia can be treated as interchangeable across ICH regions. The current Step 4 version, dated 11 November 2010, recognises Ph. Eur. 2.9.3, JP 6.10, and USP <711> as interchangeable, but only under clearly defined conditions. These include the apparatus covered by the declaration, exclusion of enzyme-containing media, GMP-compliant apparatus calibration, restrictions for delayed-release or enteric-coated dosage forms, thermometer validation if left in the vessel, exclusion of JP Interpretation 2, and exclusion of vessels larger than 1 litre. The Annex also requires product-specific parameters such as medium, stirring rate, sampling time, and sinker use to be specified and justified in the application dossier. For QC laboratories, formulation teams, Regulatory Affairs professionals, QA personnel, students, and auditors, Annex 7 is one of the most operationally important Q4B documents because it directly affects global dissolution strategy and dossier design.
What Is ICH Q4B Annex 7(R2)?
ICH Q4B Annex 7(R2) is titled Dissolution Test General Chapter. It is a Step 4 ICH Harmonised Tripartite Annex. The current R2 version is dated 11 November 2010 and reflects a second revision approved directly at Step 4 without further public consultation.
The Annex resulted from the Q4B process after the relevant dissolution texts were submitted by the Pharmacopoeial Discussion Group (PDG). Its purpose is not to create a new dissolution method, but to determine whether official regional compendial chapters can be used interchangeably and to identify the conditions that remain important for regulatory acceptance.
Annex 7 belongs to the broader ICH Quality Guidelines framework and is highly relevant to oral solid dosage-form development, release testing, stability studies, and lifecycle management.
ICH Q4B Annex 7(R2) Document History
The document-history table on page 2 of the uploaded guideline shows four key milestones:
| Date | Milestone |
|---|---|
| 13 November 2008 | Step 2 approval and release for public consultation. |
| 29 October 2009 | Step 4 approval and recommendation for adoption by the three ICH regulatory bodies. |
| 27 September 2010 | Health Canada interchangeability statement added as Annex 7(R1). |
| 11 November 2010 | Second revision approved directly under Step 4, creating the current Annex 7(R2). |
What Is Pharmaceutical Dissolution Testing?
Practical QC definition: Dissolution testing measures the rate and extent to which drug substance is released from a dosage form into a specified medium under controlled test conditions.
The Annex itself focuses on pharmacopoeial interchangeability rather than teaching the full science of dissolution. In routine pharmaceutical development and QC, dissolution testing is used to characterise dosage-form performance, support release and stability testing, and confirm conformance with approved specifications.
Which Pharmacopoeial Dissolution Tests Are Interchangeable?
Annex 7(R2) identifies the following official texts as interchangeable in ICH regions, subject to the conditions in Section 2.1:
| Pharmacopoeia | Chapter referenced in Annex 7(R2) | Subject |
|---|---|---|
| European Pharmacopoeia | Ph. Eur. 2.9.3 Dissolution Test for Solid Dosage Forms | Dissolution testing |
| JP | JP 6.10 Dissolution Test | Dissolution testing |
| USP | USP <711> Dissolution | Dissolution testing |
Which Dissolution Apparatus Are Covered by Interchangeability?
The Annex limits its general interchangeability declaration to three apparatus approaches:
Why the Flow-Through Cell needs a clear dossier reference
Annex 7 explains that the Flow-Through Cell is referred to by different apparatus numbers in the three pharmacopoeias. For this reason, the dossier should identify it by an unambiguous descriptive title or compendial reference.
Key Exclusions From Q4B Dissolution Interchangeability
Several situations are expressly outside the general interchangeability conclusion. These exclusions are central to correct use of Annex 7.
| Situation | Q4B Annex 7(R2) position |
|---|---|
| Enzymes used in dissolution media | Not considered interchangeable in the ICH regions. |
| Delayed-release, gastro-resistant, or enteric-coated dosage forms | Not considered interchangeable across the three ICH regions as a general Q4B outcome. |
| JP Interpretation 2 | Not considered interchangeable in the ICH regions. |
| Large vessels greater than 1 litre | Not considered interchangeable in the ICH regions. |
Enzymes in the medium
Where enzymes are added to the dissolution medium, Annex 7 states that the test is not considered interchangeable across the ICH regions. A company should therefore assess the current regional requirements rather than rely on the general Q4B declaration.
Delayed-release and enteric-coated dosage forms
The general Q4B outcome excludes dosage forms described regionally as delayed-release, gastro-resistant, or enteric-coated. However, the implementation section contains important region-specific positions: the EU states that it could accept the USP delayed-release dissolution approach as meeting Ph. Eur. criteria, and Canada considers the USP and Ph. Eur. delayed-release/enteric-coated dissolution tests interchangeable.
Large vessels
The Annex explicitly excludes use of large vessels greater than 1 litre from the general interchangeability conclusion. This should be checked early in method development where non-standard vessel sizes are being considered.
Dissolution Apparatus Calibration and GMP Requirements
Annex 7 requires the dissolution apparatus to be appropriately calibrated to ensure compliance with regional good manufacturing practice requirements. It specifically notes that an appropriately designed and executed mechanical calibration strategy can satisfy this expectation.
In the FDA implementation section, the Annex states that an appropriately rigorous mechanical calibration method, when properly executed, should satisfy the current good manufacturing practice requirement for dissolution apparatus calibration under 21 CFR 211.160(b)(4).
For practical quality-system implementation, calibration status, maintenance, alignment checks, dimensional checks, rotational speed, wobble, vessel condition, and related controls should be managed within the site's cGMP framework and controlled SOP system.
Thermometer in the Vessel: Validation Requirement
Annex 7 states that if a thermometer is intended to remain in the dissolution vessel during testing, validation studies should demonstrate that the test results are not adversely affected.
This requirement reflects the possibility that the physical presence of a thermometer could influence hydrodynamics or local conditions in the vessel. The validation should therefore be designed to show that leaving the thermometer in place does not alter the test result in a meaningful way.
Product-Specific Parameters Required in the Dossier
Annex 7 requires product-specific dissolution parameters to be specified and justified in the application dossier. These include:
- Dissolution medium
- Stirring rate
- Sampling time
- Use of sinkers
- Type of sinker, where applicable
This is a crucial regulatory point. Q4B may harmonise the pharmacopoeial framework, but it does not replace the need to define and justify how the test applies to the actual product.
Acceptance Criteria
Annex 7 states that acceptance criteria should be specified in the application dossier. The Annex therefore does not create a universal dissolution specification for all products.
The approved acceptance criteria should remain aligned with the product development package, regulatory filing, current pharmacopoeial requirements where applicable, and lifecycle commitments.
Regional Implementation: FDA, EU, MHLW, and Canada
| Region | Annex 7(R2) position | Practical implication |
|---|---|---|
| United States / FDA | The referenced texts can be considered interchangeable subject to Annex conditions. | FDA may request product-specific method suitability. A properly executed mechanical calibration method can satisfy the cited CGMP calibration requirement. |
| European Union | A corresponding referenced pharmacopoeial text may be accepted as fulfilling Ph. Eur. 2.9.3 under the Annex conditions. | The EU states it could accept the USP delayed-release dissolution approach as meeting Ph. Eur. criteria. Thermometer validation studies would normally be submitted in the marketing authorisation dossier. |
| Japan / MHLW | The referenced texts can be used as interchangeable according to the Annex. | MHLW states it could accept the reciprocating cylinder apparatus approach published in Ph. Eur. and USP if validation studies are submitted in the marketing authorisation dossier. |
| Canada | The cited texts can be considered interchangeable when used according to Annex conditions. | Canada specifically considers the USP and Ph. Eur. dissolution tests for delayed-release/enteric-coated products interchangeable. |
When Can ICH Q4B Annex 7(R2) Be Used?
The Annex can be used in a region after it has been incorporated into that region's regulatory process at ICH Step 5. Implementation timing can differ by region.
The Q4B FAQ explains that after regional implementation, the official pharmacopoeial texts referenced in the Annex can be used as interchangeable subject to the conditions and region-specific recommendations.
New Registrations vs Existing Products
New product registrations
For a new registration, the Q4B-evaluated pharmacopoeial text should be appropriately referenced in the application dossier. Product-specific parameters and acceptance criteria should be clearly defined and justified.
Existing product registrations
When changing an existing dissolution method to an implemented Q4B-evaluated text, any notification, variation, and/or prior approval should be handled according to established regional regulatory mechanisms for compendial changes.
Quality-System and Equipment Qualification Considerations
The Annex itself focuses on interchangeability and GMP-relevant calibration. Within a broader pharmaceutical quality system, dissolution equipment may also be controlled through lifecycle documentation such as URS, DQ, IQ, OQ, and PQ, where appropriate to site procedures.
Dissolution records should also follow ALCOA+ principles. Medium preparation, apparatus ID, temperature, rotational speed, sampling time, sinker use, calculations, chromatographic or spectrophotometric results, and approvals should remain attributable and traceable.
Practical Example: Immediate-Release Tablet
Consider an immediate-release tablet tested using Apparatus 2 in several ICH markets. If the Annex has been implemented in each region and none of the exclusions apply, the company may use one of the recognised pharmacopoeial chapters as part of a harmonised global strategy.
The dossier should still identify the medium, paddle speed, sampling time, sinker use if any, and acceptance criterion. The QC laboratory should use the current official compendial text and ensure that the dissolution tester remains appropriately calibrated.
Practical Example: Enteric-Coated Product
For an enteric-coated product, the general interchangeability declaration does not apply across all three ICH regions. The company should review the region-specific positions in Annex 7 and the current compendial requirements.
For example, Annex 7 states that the EU could accept the USP delayed-release dissolution approach as meeting Ph. Eur. criteria, while Canada considers the USP and Ph. Eur. delayed-release/enteric-coated tests interchangeable. That does not automatically create a single global rule for all regions.
Common Mistakes to Avoid
- Assuming every dissolution apparatus is interchangeable. The general declaration is limited to Basket, Paddle, and Flow-Through Cell approaches.
- Using enzyme-containing media under the general interchangeability claim. Annex 7 specifically excludes this situation.
- Ignoring the delayed-release/enteric-coated exclusion. These dosage forms require regional review.
- Using vessels larger than 1 litre without checking regional requirements. Large vessels are outside the general interchangeability conclusion.
- Leaving a thermometer in the vessel without validation. Annex 7 requires evidence that it does not adversely affect results.
- Failing to specify medium, stirring rate, sampling time, or sinker details in the dossier. These are product-specific parameters required by the Annex.
- Using an outdated pharmacopoeial chapter. The FAQ recommends the current applicable chapter for ongoing compliance.
ICH Q4B Annex 7(R2) Implementation Checklist
- Confirm the apparatus. Verify that Basket, Paddle, or Flow-Through Cell is being used if relying on the general interchangeability conclusion.
- Use an unambiguous Flow-Through Cell reference. Avoid relying only on apparatus numbering because the pharmacopoeias number it differently.
- Check the medium. If enzymes are used, do not rely on the general interchangeability declaration.
- Check dosage-form type. Review delayed-release, gastro-resistant, and enteric-coated products separately.
- Check vessel size. Vessels larger than 1 litre are outside the general interchangeability conclusion.
- Confirm calibration. Ensure the dissolution apparatus is appropriately calibrated under regional GMP requirements.
- Validate thermometer impact if applicable. Demonstrate no adverse effect if the thermometer remains in the vessel.
- Define dossier parameters. Specify and justify medium, stirring rate, sampling time, and sinker use/type.
- Specify acceptance criteria. Ensure the application dossier includes the approved criteria.
- Verify Step 5 implementation and change-control requirements. Confirm regional implementation before relying on interchangeability and assess regulatory reporting for existing products.
Key Takeaways
- ICH Q4B Annex 7(R2) covers the Dissolution Test General Chapter and is dated 11 November 2010.
- European Pharmacopoeia 2.9.3, JP 6.10, and USP <711> are interchangeable subject to Annex conditions.
- The general declaration applies to Basket Apparatus, Paddle Apparatus, and the Flow-Through Cell.
- Enzyme-containing media, JP Interpretation 2, and vessels larger than 1 litre are outside the general interchangeability conclusion.
- Delayed-release, gastro-resistant, and enteric-coated products require region-specific review.
- The dissolution apparatus should be appropriately calibrated to meet regional GMP requirements.
- Validation is required if a thermometer remains in the vessel during testing.
- Medium, stirring rate, sampling time, sinker use/type, and acceptance criteria should be specified in the application dossier.
Conclusion
ICH Q4B Annex 7(R2) provides a detailed regulatory framework for using harmonised dissolution test chapters across ICH regions. Its value lies in allowing Ph. Eur., JP, and USP dissolution procedures to be treated as interchangeable while preserving important boundaries around apparatus, media, dosage-form type, vessel size, calibration, and dossier-specific test parameters.
For pharmaceutical companies, effective implementation means more than citing USP <711>, Ph. Eur. 2.9.3, or JP 6.10. The company should confirm regional Step 5 implementation, apply the current pharmacopoeial text, control the dissolution apparatus under cGMP, justify product-specific method parameters, and manage any existing-product change through the appropriate regulatory pathway. Used correctly, Annex 7 can substantially simplify global dissolution strategy without weakening scientific or regulatory control.
Frequently Asked Questions About ICH Q4B Annex 7(R2)
1. What is ICH Q4B Annex 7(R2)?
It is the Q4B topic-specific Annex addressing regulatory interchangeability of pharmacopoeial dissolution test chapters.
2. Which pharmacopoeial dissolution chapters are interchangeable?
The Annex identifies Ph. Eur. 2.9.3, JP 6.10, and USP <711> as interchangeable subject to the stated conditions.
3. Which dissolution apparatus are covered?
The general interchangeability declaration applies to the Basket Apparatus, Paddle Apparatus, and Flow-Through Cell.
4. Are enzyme-containing dissolution media covered?
No. Annex 7 states that the dissolution test is not considered interchangeable in the ICH regions when enzymes are used in the media.
5. Are delayed-release or enteric-coated products interchangeable?
Not under the general three-region Q4B outcome. Annex 7 excludes these dosage forms, although the EU and Canada include specific regional implementation positions.
6. Are vessels larger than 1 litre interchangeable?
No. Annex 7 states that the dissolution test is not considered interchangeable for use of large vessels greater than 1 litre.
7. What calibration does Annex 7 require?
The dissolution apparatus should be appropriately calibrated to ensure compliance with regional GMP requirements. The Annex notes that a properly designed and executed mechanical calibration strategy can meet this expectation.
8. Can a thermometer remain in the dissolution vessel?
Yes, but validation studies should demonstrate that leaving the thermometer in the vessel does not adversely affect the test results.
9. What product-specific parameters must be in the dossier?
Annex 7 identifies media, stirring rate, sampling time, and use and type of sinkers as parameters that should be specified and justified in the application dossier. Acceptance criteria should also be specified.
10. Can an existing registered dissolution method be changed automatically?
No. Any notification, variation, and/or prior approval should still follow the established regional mechanisms for compendial changes.
Editorial source note: This article is an original explanatory adaptation of ICH Q4B Annex 7(R2), Dissolution Test General Chapter, together with the ICH Q4B Frequently Asked Questions dated 26 April 2012. Practical QC and quality-system explanations are included to improve usability and are clearly distinguished from source-derived requirements. This article does not replace the current pharmacopoeia, approved dossier, regional implementation requirements, or regulator guidance.
.webp)
: Dissolution Test Guide){kind=link}